ZEVALIN® Radioimmunotherapy May Play Greater Role In Combination With Standard Of Care For Various Types Of Lymphoma

... Biogen Idec Inc (Nasdaq: BIIB) announced that new data, presented today at the 47th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, December 10-13, demonstrate that patients may benefit from earlier and consolidated use of ZEVALINâ (Ibritumomab Tiuxetan) radioimmunotherapy in refractory and hard-to-treat cancers, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular non-Hodgkin''s lymphoma (FL)... click link for more info. ...